Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | HTT | P42858 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | TLR2 | O60603 | 1/20 | 0.47 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | MITF | O75030 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1616767 | 0.87 | ALDH1A1 (0.49) | ALDH1A1MEN1KMT2AGAATLR2 | |
| SCHEMBL1616714 | 0.84 | ALDH1A1 (0.47) | ALDH1A1HTTMEN1KMT2AGAA | |
| SCHEMBL1617550 | 0.84 | ALDH1A1 (0.47) | ALDH1A1MEN1KMT2ATLR2TLR1 | |
| SCHEMBL8034073 | 0.84 | TLR2 (0.49) | ALDH1A1HTTGAATLR2TLR1 | |
| SCHEMBL8475125 | 0.83 | ALDH1A1 (0.50) | ALDH1A1HTTMEN1KMT2AGAA | |
| SCHEMBL10153120 | 0.82 | ALDH1A1 (0.49) | ALDH1A1HTTTLR2TLR1SMN1; SMN2 | |
| SCHEMBL512865 | 0.82 | PSEN1 (0.50) | HTTKMT2ALMNA | |
| SCHEMBL23292585 | 0.82 | TLR2 (0.49) | ALDH1A1KMT2ATLR2TLR1LMNA | |
| SCHEMBL15442425 | 0.81 | TLR2 (0.48) | ALDH1A1TLR2TLR1MAPK1 | |
| SCHEMBL16914219 | 0.81 | TLR2 (0.44) | ALDH1A1MEN1KMT2ATLR2TLR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5859190-A | SOLID PHASE SYNTHESIS TO FORM A PROTECTED DIPEPTIDE FOLLOWED BY REACTING WITH 1,1'-THIOCARBONYLDIIMIDAZOLE TO EFFECT RING FORMATION; EFFICIENCY; ANTICONVULSANT,-ARRHYTHMIC AND DIABETIC AGENTS; HERBICIDES AND FUNGICIDES | TREGA BIOSCIENCES, INC. (US) | 1999-01-12 | — | — | US | claimed |
| WO-1998033776-A1 | COMBINATORIAL LIBRARIES OF HYDANTOIN AND THIOHYDANTOIN DERIVATIVES, METHODS OF MAKING THE LIBRARIES AND COMPOUNDS THEREIN | TREGA BIOSCIENCES, INC. (US) | 1998-08-06 | — | — | WO | claimed |
| US-9943606-B2 | Dendritic polypeptide-based nanocarriers for the delivery of therapeutic agents | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2018-04-17 | — | — | US | disclosed |
| US-20150196657-A1 | Dendritic Polypeptide-Based Nanocarriers for the Delivery of Therapeutic Agents | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2015-07-16 | — | — | US | disclosed |
| US-5859190-A | SOLID PHASE SYNTHESIS TO FORM A PROTECTED DIPEPTIDE FOLLOWED BY REACTING WITH 1,1'-THIOCARBONYLDIIMIDAZOLE TO EFFECT RING FORMATION; EFFICIENCY; ANTICONVULSANT,-ARRHYTHMIC AND DIABETIC AGENTS; HERBICIDES AND FUNGICIDES | TREGA BIOSCIENCES, INC. (US) | 1999-01-12 | — | — | US | disclosed |
| WO-1998033776-A1 | COMBINATORIAL LIBRARIES OF HYDANTOIN AND THIOHYDANTOIN DERIVATIVES, METHODS OF MAKING THE LIBRARIES AND COMPOUNDS THEREIN | TREGA BIOSCIENCES, INC. (US) | 1998-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150196657-A1 | Dendritic Polypeptide-Based Nanocarriers for the Delivery of Therapeutic Agents | CD2BP2, DCLRE1B, LNPEP | ALDH1A1 4620/4885HTT 1815/4885MEN1 2126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.